CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −10,338 | $214.72 | $2.2M | 2,300,672 |
| 2026-06-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −11,877 | $215.91 | $2.6M | 2,288,795 |
| 2026-06-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −6,741 | $216.81 | $1.5M | 2,282,054 |
| 2026-06-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −3,811 | $217.60 | $829K | 2,278,243 |
| 2026-06-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −400 | $218.72 | $87K | 2,277,843 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,536 | $209.50 | $531K | 2,375,307 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −3,267 | $210.30 | $687K | 2,372,040 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,957 | $211.61 | $626K | 2,369,083 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −12,142 | $212.27 | $2.6M | 2,356,941 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −5,034 | $213.43 | $1.1M | 2,351,907 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −5,707 | $214.35 | $1.2M | 2,346,200 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −3,161 | $215.38 | $681K | 2,343,039 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −7,182 | $216.51 | $1.6M | 2,335,857 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −4,276 | $217.32 | $929K | 2,331,581 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,133 | $218.17 | $465K | 2,329,448 |
| 2026-06-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,605 | $219.36 | $352K | 2,327,843 |
| 2026-06-05 | Marcus Gail Boxer Director | Option exercise | +11,000 | $22.83 | $251K | 17,183 |
| 2026-06-05 | Marcus Gail Boxer Director | Sale | −3,016 | $216.06 | $652K | 14,167 |
| 2026-06-05 | Marcus Gail Boxer Director | Sale | −4,694 | $217.30 | $1.0M | 9,473 |
| 2026-06-05 | Marcus Gail Boxer Director | Sale | −3,174 | $218.11 | $692K | 6,299 |
Page 16 of 39 · 767 trades